BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khot VM, Salunkhe AB, Pricl S, Bauer J, Thorat ND, Townley H. Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance. Drug Discov Today 2021;26:724-39. [PMID: 33359624 DOI: 10.1016/j.drudis.2020.12.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Słomka A, Kornek M, Cho WC. Small Extracellular Vesicles and Their Involvement in Cancer Resistance: An Up-to-Date Review. Cells 2022;11:2913. [PMID: 36139487 DOI: 10.3390/cells11182913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Rodríguez-Izquierdo I, Sepúlveda-Crespo D, Lasso JM, Resino S, Muñoz-Fernández MÁ. Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2022;14:e1774. [PMID: 35018739 DOI: 10.1002/wnan.1774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chapa-gonzález C, López K, Lomelí KM, Roacho-pérez JA, Stevens JC. A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer. Life 2022;12:327. [DOI: 10.3390/life12030327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhang RX, Liu FF, Lip H, Liu J, Zhang Q, Wu XY. Pharmaceutical nanoformulation strategies to spatiotemporally manipulate oxidative stress for improving cancer therapies — exemplified by polyunsaturated fatty acids and other ROS-modulating agents. Drug Deliv and Transl Res . [DOI: 10.1007/s13346-021-01104-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pereira AC, Pina AF, Sousa D, Ferreira D, Santos-pereira C, Rodrigues JL, Melo LDR, Sales G, Sousa SF, Rodrigues LR. Identification of novel aptamers targeting cathepsin B-overexpressing prostate cancer cells. Mol Syst Des Eng 2022;7:637-50. [DOI: 10.1039/d2me00022a] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Li J, Xie Q, Ma R, Li Y, Yuan J, Ren M, Li H, Wang J, Lu D, Xu Z, Wang J. Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System. Front Med (Lausanne) 2021;8:750170. [PMID: 34901063 DOI: 10.3389/fmed.2021.750170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Pragti, Kundu BK, Mukhopadhyay S. Target based chemotherapeutic advancement of ruthenium complexes. Coordination Chemistry Reviews 2021;448:214169. [DOI: 10.1016/j.ccr.2021.214169] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
8 Zhang Z, Zhang J, Tian J, Li H. A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1). J Nanobiotechnology 2021;19:323. [PMID: 34654435 DOI: 10.1186/s12951-021-01063-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Huang Y, Wang Y, Tang J, Qin S, Shen X, He S, Ju S. CAM-DR: Mechanisms, Roles and Clinical Application in Tumors. Front Cell Dev Biol 2021;9:698047. [PMID: 34295898 DOI: 10.3389/fcell.2021.698047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li GH, Qu Q, Qi TT, Teng XQ, Zhu HH, Wang JJ, Lu Q, Qu J. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance. J Exp Clin Cancer Res 2021;40:174. [PMID: 34011395 DOI: 10.1186/s13046-021-01974-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]